Get all premium features to the best stock analysis tool

Vancouver, British Columbia--(Newsfile Corp. - September 4, 2026) - The Precision Peptide Company Inc. (CSE: BPC) (OTCQB: PNGAF) (the "Company") announces that on July 31, 2026, it has authorized the grant of restricted share units (the "RSUs") and incentive stock options (the "Options") pursuant to the Company's omnibus share incentive plan (the "Plan"). The Company has granted 150,000 RSUs and 200,000 Options to a certain consultant of the Company.

Highlights The Company's supplement range, led by The Recovery Patch, will be available for purchase on site at FitExpo Anaheim, August 29 and 30, 2026 A 15% event discount will be available to attendees on purchases at booth 750, Anaheim Convention Center The Recovery Patch, the Company's needle-free transdermal peptide patch, achieved 95.5% chromatographic purity and a quantified 2.02 mg dose per patch in previously announced independent laboratory testing A key member of the Company's leadership team will speak on the role of peptides in biohacking as part of the Biohack Basics panel on Saturday, August 29 The appearance follows the Company's recent nationwide direct-to-consumer launch and extends its commercial rollout into live retail settings Vancouver, British Columbia--(Newsfile Corp. - August 25, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "Precision Peptide"), a publicly traded wellness company focused on advanced peptide formulations and delivery systems, is pleased to announce that it will exhibit and sell its supplement range at FitExpo Anaheim, on August 29 and 30, 2026 at the Anaheim Convention Center ("FitExpo Anaheim"). FitExpo Anaheim is a two-day consumer fitness event featuring competitions, athlete appearances and exhibitor showcases, drawing an audience of fitness, strength and wellness enthusiasts from across Southern California.

Vancouver, British Columbia--(Newsfile Corp. - August 7, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a publicly traded wellness company focused on advanced peptide formulations and delivery systems, today announced that it has completed the migration of the Amino Innovations online supplement store www.aminoinnovations.com (the "Amino Innovations Store"), including its product catalogue and existing customer base, onto the Company's e-commerce platform at www.precisionpeptidecompany.com. Following the migration, sales through the legacy Amino Innovations Store have now ceased, and all traffic is directed to the Company platform.

Highlights The Company introduces expected launch of the Peptide Pen, its second commercial product, marking a significant expansion beyond transdermal patches into precision injection delivery Designed, manufactured, and tested in the United States in a cGMP-certified facility using medical-grade materials Features a 5mL dosing configuration, a first for a combined pen-and-vial peptide device, offering significantly more capacity than the standard 3mL cartridges commonly available Interchangeable cartridge system allows customers to switch between different peptide protocols using a single device, reducing cost and complexity Commercial release targeted for August 2026 Vancouver, British Columbia--(Newsfile Corp. - August 4, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a publicly traded wellness company focused on advanced peptide formulations and delivery systems, today announces the introduction of the Peptide Pen (the "Peptide Pen"), the Company's second commercial product. The launch of the Peptide Pen is expected to represent a significant expansion of the Company's product offering, building on its BPC-157 transdermal patch with a new precision injection delivery system.